secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biofrontera Inc. (BFRI)
CIK:        0001858685
Form:       8-K
Filed at:   2022-12-16T23:59:59+00:00
Accession:  0001493152-22-035670
Event type: other_material
Sentiment:  negative
Materiality: 0.60
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biofrontera shareholders approve 94% increase in equity plan shares, elect director
--------------------------------------------------------------------------------

- Shareholders approved amendment increasing authorized shares under 2021 Omnibus Incentive Plan from 2.75M to 5,339,800 (narrowly passed: 4.77M for, 4.74M against).
- Loretta Wedge elected as Class I director for term expiring at 2025 annual meeting (7.49M for, 2.03M withheld, 2.93M broker non-votes).
- Ratification of Grant Thornton LLP as independent auditor for FY2022 approved (10.27M for, 2.06M against, 127,393 abstain).
- Amendment was previously approved by Board on Oct 20, 2022 and effective Dec 12, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1858685/000149315222035670/0001493152-22-035670-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1858685/000149315222035670/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-035670

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer